Adaptive DBS for Parkinson's Disease

This trial tests a new method to help people with Parkinson's disease improve their walking. It uses the Summit RC+S, a deep brain stimulation device that senses body movements and adjusts brain stimulation to aid walking. The trial compares two types of brain stimulation: continuous and adaptive, which changes based on movement. Suitable participants have Parkinson's disease with walking issues, such as slowed or shuffling steps, and have already had this device implanted. As an unphased trial, this study provides a unique opportunity to contribute to innovative research that could enhance mobility for those with Parkinson's.

The trial protocol does not specify whether you need to stop taking your current medications. However, since the study involves patients who have not had adequate relief from oral medications, it seems likely that you can continue your current treatment.

Research has shown that both adaptive (closed-loop) and continuous (open-loop) deep brain stimulation (DBS) are generally safe for treating Parkinson's disease. Studies have found DBS to be a safe and effective treatment for several brain-related conditions, including Parkinson’s. Long-term studies on adaptive DBS found it to be safe and effective, with no serious safety issues reported. This method adjusts stimulation based on the patient's movements, offering personalized treatment.

Continuous DBS has also been well-researched and is widely considered safe. It provides constant stimulation without adjusting for movement. Both methods use the Summit RC+S device, which previous studies have shown to reduce the need for other Parkinson’s medications, like levodopa, by more than 80%.

Researchers are excited about Adaptive DBS for Parkinson's Disease because it offers a new approach to deep brain stimulation. Unlike traditional treatments that provide continuous (open-loop) stimulation, this method includes a movement state-dependent adaptive (closed-loop) system. This means the device can adjust stimulation in real-time based on the patient's movement needs, potentially improving symptom control and reducing side effects. This tailored approach could lead to better outcomes for patients by providing more precise and effective treatment.

This trial will compare two methods of deep brain stimulation (DBS) for managing symptoms in people with Parkinson's disease. Participants in one arm will receive continuous (open-loop) DBS. Research indicates this method helps reduce movement problems and can significantly decrease the need for medications like levodopa. Participants in another arm will receive movement state-dependent adaptive (closed-loop) DBS, which might offer even better results. This method automatically adjusts its settings based on the person's movements, potentially leading to more precise symptom control and fewer side effects. Some studies suggest adaptive DBS could improve movement problems and overall quality of life in Parkinson's patients better than the traditional method. While both methods show promise, adaptive DBS might provide a more personalized treatment approach.⁶⁷⁸⁹¹⁰